Related Experiment Video
Updated: Jun 1, 2026
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice
Kiyoshi Mori1, Masashi Mukoyama, Kazuwa Nakao
1Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan. keyem@kuhp.kyoto-u.ac.jp
Abstract:
Immunosuppressants and inhibitors of the renin angiotensin system are major reagents to treat nephrotic syndrome but their clinical effects are not necessarily satisfactory. Injection of doxorubicin in several strains of mice causes nephrotic syndrome-like disorder. Zhou et al. report that PPAR-α expression is downregulated in murine doxorubicin nephropathy and a PPAR-α agonist, fenofibrate, partially ameliorates the disorder induced likely through stabilization of nephrin expression and suppression of apoptosis in podocytes, providing a new preventive strategy.
Insights
Fenofibrate, a PPAR-α agonist, shows promise in treating nephrotic syndrome by stabilizing nephrin expression and reducing podocyte apoptosis. This offers a potential new strategy beyond current immunosuppressants and renin angiotensin system inhibitors.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Nephrotic syndrome treatments like immunosuppressants and renin angiotensin system inhibitors have limited efficacy.
- Doxorubicin-induced nephropathy in mice serves as a model for studying nephrotic syndrome.
- Peroxisome proliferator-activated receptor alpha (PPAR-α) is downregulated in this murine model.
Discussion:
- Fenofibrate, a PPAR-α agonist, partially alleviates doxorubicin-induced nephrotic syndrome in mice.
- This amelioration is linked to the stabilization of nephrin expression, a key podocyte protein.
- The drug also suppresses apoptosis, programmed cell death, in podocytes.
Key Insights:
- PPAR-α activation represents a novel therapeutic target for nephrotic syndrome.
- Fenofibrate's mechanism involves protecting podocytes and maintaining glomerular filtration barrier integrity.
- Targeting PPAR-α may offer a complementary or alternative strategy to existing therapies.
Outlook:
- Further research is needed to confirm fenofibrate's efficacy and safety in human clinical trials.
- Investigating downstream pathways of PPAR-α could reveal additional therapeutic targets.
- This study opens avenues for developing targeted therapies for podocyte-related kidney diseases.
